Open AccessClinical and Virological Outcomes of TB/HIV Coinfected Patients Treated With Dolutegravir-Based HIV Antiretroviral Regimens: Programmatic Experience From Botswana
Author(s) -
Chawangwa Modongo,
Qiao Wang,
Mbatshi Dima,
Ogopotse Matsiri,
Botshelo Kgwaadira,
Goabaone Rankgoane-Pono,
Sanghyuk S. Shin,
Nicola M. Zetola
Publication year - 2019
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002126
Subject(s) - dolutegravir , medicine , regimen , odds ratio , viral load , tuberculosis , dosing , confidence interval , rifampicin , human immunodeficiency virus (hiv) , immunology , antiretroviral therapy , pathology
Dolutegravir (DTG) has recently been recommended as a preferred first-line regimen for the treatment of new and treatment-experienced HIV-infected patients. However, potential drug interactions between DTG and rifampicin remain a clinical and public health concern.